The 26 references in paper Yu. Gomon M., M. Arepyeva A., Yu. Balykina E., A. Kolbin S., A. Kurylev A., M. Proskurin A., S. Sidorenko V., Ю. Гомон М., М. Арепьева А., Ю. Балыкина Е., А. Колбин С., А. Курылев А., М. Проскурин А., С. Сидоренко В. (2018) “Прогнозирование резистентности: от математического моделирования к фармакоэкономике // Modeling microbial drug-resistance: from mathematics to pharmacoeconomics” / spz:neicon:pharmacoeconomics:y:2018:i:1:p:27-36

1
Goldmann D. A., Weinstein R. A., Wenzel R. P., et al. Strategies to prevent and control the emergence and spread of antimicrobial- resistant microorganisms in hospitals. A challenge to hospital leadership. JAMA. 1996; 275: 234-40.
(check this in PDF content)
2
Boeckel T. P. et al. Global antibiotic consumption 2000 to 2010: an analysis national pharmaceuticals sales data. Lancet Infect Dis. 2014; 14: 742-50.
(check this in PDF content)
3
Babini G. S., Livermore D. M. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother. 2000; 45: 183-9.
(check this in PDF content)
4
Paterson D. L., Ko W. C., Von Gottberg A., et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol. 2001; 39: 2206-12.
(check this in PDF content)
5
On-lain platforma analiza dannykh rezistentnosti k antimikrobnym preparatam v Rossii. URL: https://www.map.antibiotic. ru. Accessed: 25.12.2017.
(check this in PDF content)
6
Kozlov R. S., Golub A. V. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya (in Russian). 2011; 13 (4): 322-34.
(check this in PDF content)
7
Dinubile M. J., Friedland I., Chan C. Y. et al. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intraabdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. Eur J Clin Microbiol Infect Dis. 2005; 24: 443-9.
(check this in PDF content)
8
Laxminarayan R., Brown G. M. Economics of antibiotic resistance: a theory of optimal use. J Environ Econ Manage. 2001; 42: 183-206.
(check this in PDF content)
9
Walters D. J., Solomkin J. S., Paladino JA. Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intraabdominal infections. Pharmacoeconomics. 1999; 16: 551-61.
(check this in PDF content)
10
Sturkenboom M. C., Goettsch W. G., Picelli G., et al. Inappropriate initial treatment of secondary intraabdominal infections leads to increased risk of clinical failure and costs. Br J Clin Pharmacol. 2005; 60: 438-43.
(check this in PDF content)
11
Bohnen J. M. A., Solomkin J. S., Dellinger EP, et al. Guidelines for clinical care: anti-infective agents for intraabdominal infection. A Surgical Infection Society policy statement. Arch Surg. 1992; 127: 83-9.
(check this in PDF content)
12
Solomkin J. S., Mazuski J. E., Baron E. J., et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis. 2003; 37: 997-1005.
(check this in PDF content)
13
Sartelli M. et al. Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference. World Journal of Emergency Surgery. Available at: https://wjes. biomedcentral.com/articles/10.1186/s13017-017-0132-7. Accessed: 25.12.2017.
(check this in PDF content)
14
Cardoso T., Almeida M., Friedman N. D., et al. Classification of healthcare-associated infection: a systematic review 10 years after the first proposal. BMC Med. 2014; 12: 40
(check this in PDF content)
15
Basic concepts in the evaluation of medical technologies. Method. allowance. Under. Ed. A. S. Kolbin, SK Zyryanov, D. Yu. Belousov [Osnovnye ponyatiya v otsenke meditsinskikh tekhnologii. Metod. posobie. Pod. red. A. S. Kolbina, S. K. Zyryanova, D. Yu. Belousova (in Russian)]. Moscow. 2013; 42 s.
(check this in PDF content)
16
Sidorenko S. V., Kolbin A. S., Shlyapnikov S. A. Antibiotiki i khimioterapiya (in Russian). 2017; 62: 17-22.
(check this in PDF content)
17
Guilbart M. et al. Compliance with an empirical antimicrobial protocol improves the outcome of complicated intra-abdominal infections: a prospective observational study. Br J Anaesth. 2016; 117 (1): 66-72.
(check this in PDF content)
18
Commission for the development of the Territorial Program of CHI in St. Petersburg. General Tariff Agreement (in Russian). URL: https://spboms.ru/page/docs. Accessed: 25.12.2017.
(check this in PDF content)
19
The price list of paid medical services of SPb GBU “Institute of Emergency care named after I. I. Janelidze» (in Russian). URL: http:// www.emergency.spb.ru/services/paid/328-price. Accessed: 25.12.2017.
(check this in PDF content)
20
Arepyeva M., Kolbin A., Sidorenko S. et al. A mathematical model for predicting the development of bacterial resistance based on the relationship between the level of antimicrobial resistance and the volume of antibiotic consumption. Journal of Global Antimicrobial Resistance. 2017; 8: 148-156.
(check this in PDF content)
21
Arep’eva M. A., Kolbin A. S., Sidorenko S. V. Klinicheskaya mikrobiologiya antimikrobnaya khimioterapiya (in Russian). 2016; 18 (3): 200-211.
(check this in PDF content)
22
The WHO global strategy for containment of antimicrobial resistance. URL: http://www.who.int/drugresistance/WHO_Global_ Strategy_Russian.pdf. Accessed: 25.12.2017.
(check this in PDF content)
23
Gomon Yu. M., Balykina Yu. E., Kolbin A. S. Research report. 2017.
(check this in PDF content)
24
Daneman N., Hong Lu, Redelmeier D. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open. 2015; 5:e010077: 1-9. DOI: 10.1136/bmjopen-2015-010077.
(check this in PDF content)
25
Arcieri G. M., Becker N., Esposito B. et al. Safety of intravenous ciprofloxacin. A review. Am J Med. 1989; 87 (5A): 92-97.
(check this in PDF content)
26
Etminan M., Forooghian F., Brophy J. M., et al. Oral fluoroquinolones and the risk of retinal detachment. JAMA. 2012; 307 (13): 1414-9. Сведения об авторах: Гомон Юлия Михайловна – к. м.н., ассистент кафедры клинической фармакологии и доказательной медицины ФГБОУ ВО «ПСПбГМУ им. И. П. Павлова»
(check this in PDF content)